Genmab (GMAB) has released an update.
Genmab’s epcoritamab (TEPKINLY®) has garnered a positive CHMP opinion for treating relapsed or refractory follicular lymphoma in adults, potentially becoming the first bispecific antibody monotherapy approved in the EU for this condition. The recommendation is based on promising data from the EPCORE® NHL-1 trial, which demonstrated significant response rates and manageable side effects in patients. This development marks a critical advancement for those with limited treatment options, as epcoritamab aims to offer a new therapeutic possibility for a challenging disease.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
